PTC Therapeutics | PTCT

PTC Therapeutics traded at $45.12 this Tuesday March 28th, decreasing $0.64 or 1.40 percent since the previous trading session. Looking back, over the last four weeks, PTC Therapeutics lost 0.27 percent. Over the last 12 months, its price rose by 16.02 percent. Looking ahead, we forecast PTC Therapeutics to be priced at 42.77 by the end of this quarter and at 38.81 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Daiichi Sankyo 4,640.00 -10.00 -0.22% 71.92%
Acadia Pharmaceuticals 18.43 -0.17 -0.91% -27.21%
Alnylam Pharmaceuticals 188.55 -1.96 -1.03% 13.08%
Amgen 238.48 1.72 0.73% -1.27%
BioCryst Pharmaceuticals 8.59 0.13 1.54% -49.80%
Biogen 270.25 0.27 0.10% 25.73%
Bluebird Bio 4.32 -0.19 -4.21% -16.92%
BioMarin Pharmaceutical 91.44 -0.06 -0.07% 14.93%
Cytokinetics 34.98 0.45 1.30% -8.95%
Enanta Pharmaceuticals 38.82 -1.00 -2.51% -44.70%
Esperion Therapeutics 1.76 0.08 4.76% -64.52%
Gilead Sciences 80.97 1.39 1.75% 35.72%
Intercept Pharmaceuticals 13.65 -0.18 -1.30% -19.56%
Incyte Corp 70.31 -0.50 -0.71% -11.79%
Ionis Pharmaceuticals 34.29 0.57 1.69% -6.00%
Ironwood Pharmaceuticals 10.59 -0.23 -2.13% -17.78%
Karyopharm Therapeutics 3.51 0.02 0.57% -54.47%
Novartis 82.82 -0.65 -0.78% 1.43%
Puma Biotechnology 2.46 0.08 3.36% -15.75%
Pfizer 39.99 -0.23 -0.57% -24.18%
PTC Therapeutics 45.12 -0.64 -1.40% 16.02%
Ultragenyx Pharmaceutical 37.66 0.33 0.88% -47.32%
Roche Holding 260.30 3.35 1.30% -29.80%
Sangamo BioSciences 1.70 -0.04 -2.30% -72.93%
Sarepta Therapeutics 133.90 2.76 2.10% 70.10%
TG Therapeutics 14.65 -0.35 -2.33% 38.73%
Vertex Pharmaceuticals 313.25 4.78 1.55% 21.42%
Xencor 27.86 -0.26 -0.92% -3.13%

Indexes Price Day Year
USND 11716 -52.76 -0.45% -19.86%
US2000 1753 -1.04 -0.06% -17.84%

PTC Therapeutics
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).